NO955063D0 - Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav - Google Patents

Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav

Info

Publication number
NO955063D0
NO955063D0 NO955063A NO955063A NO955063D0 NO 955063 D0 NO955063 D0 NO 955063D0 NO 955063 A NO955063 A NO 955063A NO 955063 A NO955063 A NO 955063A NO 955063 D0 NO955063 D0 NO 955063D0
Authority
NO
Norway
Prior art keywords
clone
mhc molecule
form complexes
isolated peptides
tumor rejection
Prior art date
Application number
NO955063A
Other languages
English (en)
Other versions
NO955063L (no
Inventor
Pierre Van Der Bruggen
Thierry Boon-Falleur
Pierre G Coulie
Jean-Christophe Renauld
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO955063D0 publication Critical patent/NO955063D0/no
Publication of NO955063L publication Critical patent/NO955063L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO955063A 1993-06-17 1995-12-14 Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav NO955063L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/079,110 US5571711A (en) 1993-06-17 1993-06-17 Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US08/196,630 US5683886A (en) 1993-06-17 1994-02-15 Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof
PCT/US1994/006534 WO1995000159A1 (en) 1993-06-17 1994-06-10 Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof

Publications (2)

Publication Number Publication Date
NO955063D0 true NO955063D0 (no) 1995-12-14
NO955063L NO955063L (no) 1996-01-24

Family

ID=22148499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955063A NO955063L (no) 1993-06-17 1995-12-14 Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav

Country Status (13)

Country Link
US (7) US5571711A (no)
EP (1) EP0711173B1 (no)
JP (1) JP3477523B2 (no)
KR (1) KR100306464B1 (no)
CN (1) CN1230535C (no)
AT (1) ATE267254T1 (no)
AU (1) AU677680B2 (no)
DE (1) DE69433790T2 (no)
FI (1) FI956019A (no)
NO (1) NO955063L (no)
NZ (1) NZ268490A (no)
WO (1) WO1995000159A1 (no)
ZA (1) ZA944196B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
US5877017A (en) * 1993-06-17 1999-03-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
DE19543649C2 (de) * 1995-11-23 1998-01-29 Boehringer Ingelheim Int Tumorvakzine und Verfahren zu ihrer Herstellung
US5837476A (en) * 1995-03-03 1998-11-17 Ludwig Institute Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
AU727028B2 (en) * 1996-06-25 2000-11-30 Ludwig Institute For Cancer Research Brain glycogen phosphorylase cancer antigen
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
PT970206E (pt) 1997-01-27 2008-10-28 Ludwig Inst Cancer Res Ácidos nucleicos lage-1 associados a tumores
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US5879892A (en) * 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
US5905145A (en) * 1998-03-06 1999-05-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
SE0000410D0 (sv) * 2000-02-06 2000-02-06 Lennart Hoeglund Trefas transformatorkärna
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1268394C (zh) 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US20040180354A1 (en) * 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
EP2292638A3 (en) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE-C2 antigenic peptides and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
CA2529056C (en) * 2003-06-17 2013-09-10 Mannkind Corporation Combinations of tumor-associated antigens in compositions for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
WO2006083305A2 (en) * 2004-06-23 2006-08-10 University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
US7309589B2 (en) * 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
SG158154A1 (en) * 2004-12-29 2010-01-29 Mannkind Corp Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
SG162818A1 (en) * 2005-06-17 2010-07-29 Mannkind Corp Multivalent entrain-and-amplify immunotherapeutics for carcinoma
EP2089423B1 (en) 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2010080909A1 (en) 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
EP2861761A1 (en) 2012-06-15 2015-04-22 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US20160024493A1 (en) 2013-03-15 2016-01-28 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
WO2015058111A1 (en) 2013-10-17 2015-04-23 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and thereapeutic agents
US9172477B2 (en) 2013-10-30 2015-10-27 Inthinc Technology Solutions, Inc. Wireless device detection using multiple antennas separated by an RF shield
EP3140269B1 (en) 2014-05-09 2023-11-29 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
WO2016168197A1 (en) 2015-04-15 2016-10-20 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
US11090391B2 (en) 2016-09-16 2021-08-17 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
US20200085758A1 (en) 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2018237109A1 (en) 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
US20230293448A1 (en) 2021-12-08 2023-09-21 Yale University Nanoparticle immunogenic compositions and vaccination methods
WO2023147552A1 (en) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
EP0507772A1 (en) * 1989-04-26 1992-10-14 Sloan-Kettering Institute For Cancer Research Non-melanocytic, eucaryotic cell constitutively expressing biologically active human tyrosinase and use thereof
AU1998192A (en) 1991-05-20 1992-12-30 Big Unlimited Method and apparatus for creating design insulated glass
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors

Also Published As

Publication number Publication date
EP0711173A4 (en) 1998-04-15
EP0711173B1 (en) 2004-05-19
EP0711173A1 (en) 1996-05-15
US6638512B1 (en) 2003-10-28
KR960703014A (ko) 1996-06-19
NO955063L (no) 1996-01-24
US20030138854A1 (en) 2003-07-24
DE69433790D1 (de) 2004-06-24
DE69433790T2 (de) 2004-10-07
US6110694A (en) 2000-08-29
US5571711A (en) 1996-11-05
ZA944196B (en) 1995-05-11
NZ268490A (en) 1997-12-19
WO1995000159A1 (en) 1995-01-05
FI956019A (fi) 1996-01-25
JPH09502863A (ja) 1997-03-25
JP3477523B2 (ja) 2003-12-10
AU7171694A (en) 1995-01-17
CN1102213A (zh) 1995-05-03
US5683886A (en) 1997-11-04
ATE267254T1 (de) 2004-06-15
KR100306464B1 (ko) 2001-11-30
US6093540A (en) 2000-07-25
FI956019A0 (fi) 1995-12-14
AU677680B2 (en) 1997-05-01
CN1230535C (zh) 2005-12-07
US6465184B1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
NO955063D0 (no) Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav
EP0845032A4 (en) ISOLATED NUCLEIC ACID MOLECULES, PEPTIDES FORMING COMPLEXES WITH THE MOLECULE OF THE MAJOR HLA-A2 HISTOCOMPATIBILITY COMPLEX (MHC) AND THEIR APPLICATIONS
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
FI960268A0 (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
NO953601D0 (no) Nukleinsyre som koder for en tumorreksjonsantigenforlöper
HK1008228A1 (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
CA2213001A1 (en) Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof
CA2165435A1 (en) Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
UA66753C2 (en) Immunostimulator and method for its production

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application